Publikace

Srovnání publikační aktivity - MM v časopisech s IF

2009 2010 2011 2012 2013 2014 2015 2016
Periodikum IF Periodikum IF Periodikum IF Periodikum IF Periodikum IF Periodikum IF Periodikum IF Periodikum IF
Blood
10,432
J Clin Oncol (2x)
17,793
Blood (2x)
10,558
N Engl J Med
53,298
Lancet Oncol
25,117
Lancet Oncol
24,725
N Engl J Med (2x)
54,42
N Engl J Med (2x) 55,873
Leukemia (3x)
8,634
Leukemia
8,296
Leukemia (1x)
8,966
J Clin Oncol
18,372
J Clin Oncol (2x)
18,038
J Clin Oncol
17,879
J Clin Oncol
17,879
Lancet Oncol 24,69
Leuk Res 
2,39
Haematologica
6,416
Haematologica
6,532
Leukemia 
9,561
Leukemia (2x)
10,164
Blood
9,775
Blood
9,775
Blood (2x) 10,452
Eur J Haematol
2,237
Brit J Haematol (2x)
4,597
Eur J Haematol (2x)
2,785
Haematologica (2x)
6,424
Haematologica 
5,935
Leukemia
9,379
Haematologica (2x)
5,868
Oncotarget  6,359
Leuk Lymphoma
1,939
Biol Blood Marrow Transplant
3,149
Ann Hematol
2,688
Br J Haematol 
4,941
Br J Haematol
4,942
Haematologica 
5,868
Br J Haematol
4,959
Blood Rev 5,451
Clin Chem Lab Med
1,741
Clin Nucl Med
3,915
Leuk Res (2x)
2,555
PLoS One (2x)
4,092
J Transl Med
3,459
Br J Haematol
4,959
J Mol Diagn
3,955
Cancer 4,889
Clin Lymphoma Myeloma (2x)
1,596
Ann Hematol (2x)
2,919
Leuk Lymphoma (1x)
2,492
J Transl Med
3,474
Genomics
3,010
Oncologist
4,54
PLoS One (2x)
3,534
Crit Rev Oncol Hematol 4,027
Onkologie
1,545
Leuk Res (1x)
2,358
Mol Biotechnol
2,091
BMC Cancer
3,011
Clin Chem Lab Med
3,009
J Cell Mol Med
3,698
Am J Haematol
3,477
J Transl Med 3,93
Cancer Genet Cytogenet
1,482
Leuk Lymphoma (2x)
2,397
Clin Chem Lab
2,069
Leuk Res 
2,923
Leuk Res (3x)
2,764
Biomed Res Int
2,706
Leuk Lymphoma
2,605
Am J Haematol (2x) 3,798
Neoplasma (3x)
1,179
Mol Biotechnol
2,444
Clin Biochem
2,043
Leuk Lymphoma (5x)
2,580
Leuk Lymphoma (3x)
2,301
Leuk Lymphoma
2,605
Eur J Haematol 
2,414
Leuk Lymphoma 2,891
    Int J Hematol
1,168
Clin Lymphom Myelom Leuk (3x)
1,988
Clin Chem Lab Med
2,150
Hematol Oncol
2,036
Cancer Genet
2,417
Clin Lymphoma Myeloma Leuk
1,929
Eur J Haematol (4x) 2,414
    Neoplasma (6x)
1,192
Neoplasma (2x)
1,449
Neoplasma 
1,440
Clin Lymphoma Myeloma Leuk
1,667
Cytometry B Clin Cytom
2,231
Biomed Pap (4x) 
1,661
Clin Lymphoma Myeloma Leuk 2,316
    Wien Klin Wochenschr
0,955
Amyloid
1,433
        Clin Lymphoma Myeloma Leuk
1,929
Neoplasma
1,642
Biomed Pap (2x) 0,924
        Immunotherapy
0,542
        Int Med J
1,699
J Negat Result Biomed
1,.47
   
                    Neoplasma
1,642
Č a S neurol neuroch (2x)
0,159
   
Počet publikací s IF 15 Počet publikací s IF 23 Počet publikací s IF 20 Počet publikací s IF 18 Počet publikací s IF 18 Počet publikací s IF 20 Počet publikací s IF 22 Počet publikací s IF 20
Celkový IF 2009 54,397 Celkový IF 2010 93,623 Celkový IF 2011 69,514 Celkový IF 2012 133,102 Celkový IF 2013 120,774 Celkový IF 2014 125,637 Celkový IF 2015 184,711 Celkový IF 2016 206,303

Graf

Publikace 2017

MM a MGUS

  1. Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176 IF 10,431
  2. Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hájek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017 Jan;31(1):115-122. doi: 10.1038/leu.2016.186. IF 10,431
  3. Schneiderova P, Pika T, Gajdos P, Fillerova R, Kromer P, Kudelka M, Minarik J, Papajik T, Scudla V, Kriegova E. Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma. Oncotarget. 2016 Aug 12. doi: 10.18632/oncotarget.11242. [Epub ahead of print] IF 6,359
  4. Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol. 2016 Sep 6. pii: JCO669648. [Epub ahead of print] IF 18,428
  5. Všianská P, Bezděková R, Kryukov F, Almáši M, Pour L, Penka M, Hájek R, Říhová L. Activity of aldehyde dehydrogenase in B-cell and plasma cell subsets of monoclonal gammopathy patients and healthy donors. Eur J Haematol. 2017 Jan;98(1):19-25. doi: 10.1111/ejh.12779. IF 2,414

Jiné výzkumné projekty 2017

  1. Filipova J, Rihova L, Vsianska P, Kufova Z, Kryukova E, Kryukov F, Hajek R. Flow cytometry in immunoglobulin light chain amyloidosis: Short review. Leuk Res. 2015 Jul 13. pii: S0145-2126(15)30345-3. doi: 10.1016/j.leukres.2015.07.002. [Epub ahead of print] Review. IF 2,692
  2. Jelinek T, Kryukova E, Kufova Z, Kryukov F, Hajek R. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. Hematol Oncol. 2016 Sep 20. doi: 10.1002/hon.2351. [Epub ahead of print] Review. IF 3,084

 

Publikace 2016

MM a MGUS

  1. Adam Z, Pourová E, Pour L, Michalková E, Krejčí M, Koukalová R, Řehák Z, Vaníček J, Nebeský T, Petrášová H, Ševčíková S, Mašek M, Král Z, Čermák A. The patient complains of spinal pain or fatigue and weakness. How do I recognize whether their cause is spondylarthrosis, the patients age or multiple myeloma? Vnitr Lek. 2016 Feb;62(2):114-24. Czech.
  2. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596. IF 10,452
  3. Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Jelinek T, Pour L, Adam Z, Kuglik P, Krejci M, Hajek R, Sevcikova S. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016 Jul;97(1):93-100. doi: 10.1111/ejh.12688.IF 2,414
  4. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. IF 24,69
  5. Jelinek T, Hajek R. Monoclonal antibodies - A new era in the treatment of multiple myeloma. Monoclonal antibodies - A new era in the treatment of multiple myeloma. Blood Rev. 2016 Mar;30(2):101-10. doi: 10.1016/j.blre.2015.08.004.IF 5,451
  6. Jurczyszyn A, Olszewska-Szopa M, Hungria V, Crusoe E, Pika T, Delforge M, Leleu X, Rasche L, Nooka AK, Druzd-Sitek A, Walewski J, Davila J, Caers J, Maisnar V, Gertz M, Gentile M, Fantl D, Mele G, Vesole DH, Yee AJ, Shustik C, Lentzsch S, Zweegman S, Gozzetti A, Skotnicki AB, Castillo JJ. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 Sep;57(9):2071-6. doi: 10.3109/10428194.2015.1128542. IF 2,891
  7. Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 Jun;91(6):575-80. doi: 10.1002/ajh.24351. IF 3,798
  8. Kryukov F, Nemec P, Radova L, Kryukova E, Okubote S, Minarik J, Stefanikova Z, Pour L, Hajek R. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J Transl Med. 2016 May 28;14(1):150. doi: 10.1186/s12967-016-0906-9. IF 3,93
  9. Kryukova E, Kryukov F, Hajek R. Centrosome amplification and clonal evolution in multiple myeloma: Short review. Crit Rev Oncol Hematol. 2016 Feb;98:116-21. doi: 10.1016/j.critrevonc.2015.10.019. Review. IF 4,027
  10. Leleu X, Terpos E, Sanz RG, Cooney J, O'Gorman P, Minarik J, Greil R, Williams C, Gray D, Szabo Z. An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). Am J Hematol. 2016 Aug;91(8):806-11. doi: 10.1002/ajh.24416. IF 3,798
  11. Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. IF 10,452
  12. Mikulasova A, Smetana J, Wayhelova M, Janyskova H, Sandecka V, Kufova Z, Almasi M, Jarkovsky J, Gregora E, Kessler P, Wrobel M, Walker BA, Wardell CP, Morgan GJ, Hajek R, Kuglik P. Genome-wide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. Eur J Haematol. 2016 Dec;97(6):568-575. doi: 10.1111/ejh.12774. IF 2,414
  13. Minarik J, Krhovska P, Hrbek J, Pika T, Bacovsky J, Herman M, Scudla V. Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jun;160(2):305-9. doi: 10.5507/bp.2015.064. IF 0,924
  14. Minarik J, Hermanova Z, Petrova P, Hrbek J, Zapletalova J, Krhovska P, Flodr P, Pika T, Bacovsky J, Flodrova P, Herman M, Scudla V. Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers. Eur J Haematol. 2016 Aug;97(2):201-7. doi: 10.1111/ejh.12708. IF 2,414
  15. Mlynarcikova M, Balcarkova J, Mickova P, Scudla V, Pika T, Bacovsky J, Minarik J, Janousova E, Jarosova M. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse. Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):358-65. doi: 10.1016/j.clml.2016.02.038. IF 2,316
  16. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282. IF 55,873
  17. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. doi: 10.1002/cncr.30026. IF 4,889
  18. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. IF 55,873
  19. Radocha J, Pour L, Pika T, Maisnar V, Špička I, Gregora E, Krejčí M, Minařík J, Machálková K, Straub J, Pavlíček P, Hájek R, Žák P. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. Eur J Haematol. 2016 Feb;96(2):119-27. doi: 10.1111/ejh.12556. IF 2,414
  20. Scudla V, Lochman P, Pika T, Minarik J, Zapletalova J, Bacovsky J. Relationship of differences in immunoglobulin heavy/light chain pairs (HevyliteTM), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):84-93. doi: 10.5507/bp.2015.032. IF 0,924
  21. Ščudla V, Balcárková J, Lochman P, Vincová M, Pika T, Minařík J, Zapletalová J, Jarošová M. Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System]. Vnitr Lek. 2016 Apr;62(4):269-80. Czech.
  22. Štork M, Krejčí M, Sandecká V, Král Z, Pour L. Use of new drugs within primary therapy of multiple myeloma. Vnitr Lek. 2016 Spring;62(5):413-22. Czech.
  23. Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, Greil R, Jöhrer K. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. Oncotarget. 2016 Nov 29;7(48):78605-78618 IF 6,359

Jiné výzkumné projekty 2016

  1. Adam Z, Mašlaň J, Křen L, Kodet R, Koukalová R, Řehák Z, Červinek L, Pour L, Krejčí M, Sandecká V, Král Z, Mayer J. Sinus histiocytosis with massive lymphadenopathy: FDG-PET/CT documented partial remission after treatment with 2-chlorodeoxyadenosine. Vnitr Lek. 2016 Summer;62(6):491-9. Czech.
  2. Adam Z, Szturz P, Krejčí M, Koukalová R, Michalková E, Řehák Z, Pourová E, Pour L, Volfová P, Sandecká V, Čermáková Z, Křen L, Sokol F, Hanke I, Penka I, Petrášová H, Ševčíková S, Král Z, Mayer J. Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature. Vnitr Lek. 2016 Apr;62(4):287-98. Review. Czech.
  3. Adam Z, Pour L, Krejčí M, Ševčíková S, Pourová E, Ševčíková E, Král Z, Mayer J. Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience. Vnitr Lek. 2016 Jan;62(1):25-39. Review. Czech.
  4. Adam Z, Šedivá A, Koukalová R, Řehák Z, Petrášová H, Szturz P, Adamová Z, Vetešníková E, Pour L, Krejčí M, Sandecká V, Pourová E, Čermáková Z, Ševčíková S, Král Z, Mayer J. Schnitzlers Syndrome Differential diagnostics, an overview of therapeutic options and description of 5 cases treated with anakinra. Vnitr Lek. 2016 Fall;62(9):713-727. Czech.
  5. Fikrle M, Palecek T, Masek M, Kuchynka P, Straub J, Spicka I, Rysava R, Linhart A. The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis. Clin Physiol Funct Imaging. 2016 May;36(3):218-24. doi: 10.1111/cpf.12216. IF 1,376
  6. Gromesová B, Kubaczková V, Bollová B, Sedlaříková L, Ševčíková S. Potential of Long Non- coding RNA Molecules in Diagnosis of Tumors. Klin Onkol. 2016;29(1):20-8. Review. Czech.
  7. Jelinek T, Kufova Z, Hajek R. Immunomodulatory drugs in AL amyloidosis. Crit Rev Oncol Hematol. 2016 Mar;99:249-60. doi: 10.1016/j.critrevonc.2016.01.004. Review. IF 4,027
  8. Kryukov F, Kryukova E, Brozova L, Kufova Z, Filipova J, Growkova K, Sevcikova T, Jarkovsky J, Hajek R. Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. Gene. 2016 Oct 15;591(2):490-8. doi: 10.1016/j.gene.2016.06.017. IF 2,138
  9. Kutálková K, Sedlaříková L, Adam Z, Ševčíková S. Gene mutations connected to Waldenstöm macroglobulinemia. Vnitr Lek. 2016 Jan;62(1):40-3. Review. Czech.

Publikace 2015

MM a MGUS

  1. Bacovsky J, Myslivecek M, Minarik J, Scudla V, Pika T, Zapletalova J, Petrova P, Bartkova M, Adam T, Gronowitz SJ. Analysis of thymidine kinase serum levels by novel method DiviTum™ in multiple myeloma and monoclonal gammopathy of undetermined significance-comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):135-8. doi: 10.5507/bp.2014.008. IF 1,661
  2. Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O, Kuglik P, Almasi M, Penka M, Krejci M, Adam Z, Pour L, Sevcikova S, Hajek R. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLoS One. 2015;10(9):e0137294. doi: 10.1371/journal.pone.0137294. eCollection 2015. IF 3,534
  3. Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. J Mol Diagn. 2015;17(6):652-60. pii: S1525-1578(15)00147-6. doi: 10.1016/j.jmoldx.2015.05.007. IF 3,955
  4. Hrabálek L, Wanek T, Bačovský J, Minařík J, Ščudla V. Algoritmus operací mnohočetného myelomu a solitárního plazmocytomu páteře. Česká a Slovenská neurologie a neurochirurgie. 2015;78/111(1): 64-71. IF 0,159
  5. Jelinek T, Vsianska P, Hajek R. Monoklonální protilátky v léčbě mnohočetného myelomu, Transfuze Hematol. Dnes 21, 2015, No. 2, p. 74-83
  6. Jelinek T, Kryukov F, Rihova L, Hajek R. Plasma cell leukemia: from biology to treatment. Eur J Haematol. 2015 Jul;95(1):16-26 IF 2,414
  7. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621-31. doi: 10.1056/NEJMoa1505654. IF 54,42
  8. Ludwig H, Rauch E, Kuehr T, Adam Z, Weissmann A, Kasparu H, Autzinger EM, Heintel D, Greil R, Poenisch W, Müldür E, Zojer N. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica. 2015;100(3):385-91, pii: haematol.2014.115204. IF 5,868
  9. Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Chaturvedi S, Ataman O, Enny C, Feng H, van de Velde H, Viterbo L. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Br J Haematol. 2015;171(3):344-54. doi: 10.1111/bjh.13582. IF 4,959
  10. Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J, Straub J, Kessler P, Wrobel M, Walterova L, Sykora M, Obernauerova J, Brozova L, Gregora E, Adamova D, Gumulec J, Adam Z, Scudla V, Hajek R; Czech Myeloma Group. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One. 2015;10(4):e0123866. doi: 10.1371/journal.pone.0123866. eCollection 2015. IF 3,534
  11. Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015;56(12):3320-8.IF 2,605
  12. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Spička I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma. Am J Hematol. 2015;90(1):42-9. doi: 10.1002/ajh.23868. IF 3,477
  13. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report. Blood. 2015;125(13):2068-74 pii: blood-2014-12-615187.  IF 9,775
  14. Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2015;33(30):3459-66. pii: JCO.2014.60.2466. IF 17,879
  15. Pika T, Lochman P, Sandecka V, Maisnar V, Minarik J, Tichy M, Zapletalova J, Solcova L, Scudla V, Hajek R. Immunoparesis in MGUS - Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. Neoplasma. 2015;62(5):827-32. doi: 10.4149/neo_2015_100. IF 1,642
  16. Pika T, Folprechtová P, Roubalová R, Lochman P, Ščudla V. Úspěšná léčba anti‑MAG neuropatie asociované s monoklonální gamapatií nejistého významu kombinací rituximabu s dexametazonem – kazuistika. Cesk Slov Neurol N. 2015, 78(4): 474-476 IF 0,159
  17. Sedlarikova L, Kubiczkova L, Kryukov F, Pelcova J, Adam Z, Pour L, Hajek R, Sevcikova S. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(4):554-61.  doi: 10.5507/bp.2014.035. IF 1,661
  18. Sedlaříková L, Bešše L, Novosadová S, Kubaczková V, Radová L, Staník M, Krejčí M, Hájek R, Ševčíková S. MicroRNAs in urine are not biomarkers of multiple myeloma. J Negat Results Biomed. 2015;14(1):16. doi: 10.1186/s12952-015-0035-7. IF 1,47
  19. Sevcikova S, Paszekova H, Besse L, Sedlarikova L, Kubaczkova V, Almasi M, Pour L, Hajek R. Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):288-93. doi: 10.5507/bp.2015.014. IF 1,661
  20. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-52. doi: 10.1056/NEJMoa1411321. IF 54,42
  21. Ščudla V, Pika T, Minařík J. The role of the assessment of heavy/light chain pairs of immunoglobulin in monoclonal gammopathies. Vnitr Lek. 2015;61(1):60-71.
  22. Ščudla V, Petrová P, Pika T, Lochman P, Minařík J, Bačovský J, Srovnalík K. Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma. Cas Lek Cesk. 2015;154(4):181-8.
  23. Ščudla V, Lochman P, Pika T, Zapletalová J, Minařík J, Bačovský J: Vyšetření párů těžkých/lehkých řetězců imunoglobulinu (Hevylite TM)- přínos pro stratifikaci mnohočetného myelomu? Klin Onkol 2015; 28(5): 359-369.
  24. Ščudla V, Lochman P, Pika T, Zapletalová J, Minařík J, Bačovský J. Analýza vztahu sérových hladin těžkých/lehkých řetězců imunoglobulinu (HevyliteTM) k výsledkům standardní gelové elektroforézy a nefelometrického vyšetření bílkovin séra při diagnóze mnohočetného myelomu. Cas Lek Cesk. 2015;28(5):359-69.
  25. Scudla V, Lochman P, Pika T, Minarik J, Zapletalova J, Bacovsky J. Relationship of differences in immunoglobulin heavy/light chain pairs (HevyliteTM), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):84-93. doi: 10.5507/bp.2015.032.IF 1,661
  26. Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; European Myeloma Network. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica. 2015;100(10):1254-66. doi: 10.3324/haematol.2014.117176. IF 5,868
  27. Všianská P, Říhová L, Varmužová T, Suská R, Kryukov F, Mikulášová A, Kupská R, Penka M, Pour L, Adam Z, Hájek R. Analysis of B-Cell Subpopulations in Monoclonal Gammopathies. Clin Lymphoma Myeloma Leuk. 2015;15(4)e61-71 doi: 10.1016/j.clml.2014.12.003. IF 1,929

Jiné výzkumné projekty

  1. Adam Z, Szturz P, Koukalová R, Řehák Z, Pour L, Krejčí M, Šmardová L, Eid M, Volfová P, Čermáková Z, Křen L, Sokol F, Hanke I, Michalková E, Král Z, Mayer J. PET-CT documented remission of multicentric Castleman disease after treatment with rituximab: case report and review. Vnitr Lek. 2015;61(3):251-9. 
  2. Adam Z, Kissová J, Pour L, Krejčí M, Ševčíková E, Koukalová R, Čermáková Z, Černá M, Král Z, Mayer J. Myopatie při Waldenströmově makroglobulinemii. Popis případu a přehled autoimunitních projevů monoklonálních imunoglobulinů typu IgM. Vnitř Lék 2015; 61(9): 821-828.
  3. Adam Z, Litzman J, Szturz P, Krejčí M, Vašků V, Pour L, Michalková E, Ševčíková S, Čermáková Z, Veselý K, Vaníček J, Pourová E, Král Z. Scleroedema adultorum Buschke a scleromyxedema. Česká dermatovenerologie 2015; 5(3):150-158.
  4. Fiserova B, Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. The miR-29 family in hematological malignancies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):184-91. doi: 10.5507/bp.2014.037. IF 1,661
  5. Kubaczková V, Sedlaříková L, Bešše L, Almaši M, Hájek R, Ševčíková S. Potential of Cellfree Circulating DNA in Diagnosis of Cancer. Klin Onkol. 2015;28(4):251-9.
  6. Kubiczkova Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Almasi M, Pelcova J, Minarik J, Pika T, Pikalova Z, Scudla V, Krejci M, Adam Z, Pour L, Hajek R, Sevcikova S. Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia. Am J Hematol. 2015;90(3):E51-2. doi: 10.1002/ajh.23910. IF 3,477
  7. Palecek T, Fikrle M, Nemecek E, Bauerova L, Kuchynka P, Louch WE, Spicka I, Rysava R. Contemporary treatment of amyloid heart disease. Curr Pharm Des. 2015;21(4):491-506. Review. IF 3,288
  8. Pika T, Lochman P, Latalova P, Minařik J, Puščiznova P, Bačovsky J, Ščudla V. Problematika stanoveni monoklonalniho imunoglobulinu u nemocnych s AL amyloidozou. Klin. Biochem. Metab., 23 (44), 2015, No. 2, p. 37–41.
  9. Pika T, Lochman P, Kušnierova P, Heřmanova Z, Zapletalova J, Puščiznova P,Minařik J, Ščudla V. Stanoveni parů těžkych/lehkych řetězců imunoglobulinu u nemocnych s nově diagnostikovanou Waldenströmovou makroglobulinemii. Klin. Biochem. Metab., 23 (44), 2015, No. 2, p. 42–47.

 

Publikace 2014

MM a MGUS

  1. Adam Z, Krejčí M, Pour L, Sevčíková E, Křivanová A, Rehák Z, Koukalová R, Cermáková Z, Vaníček J, Sevčíková S. Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014. Vnitr Lek. 2014 Oct;60(10):861-79.
  2. Dimopoulos MA, Palumbo A, Hajek R, Kropff M, Petrucci MT, Lewis P, Millar S, Zhang J, Mei J, Delforge M. Factors that influence health-related quality of life in newly diagnosed multiple myeloma patients aged ≥ 65 years treated with melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leuk Lymphoma. 2014;55(7):1489-97. doi: 10.3109/10428194.2013.847933. IF 2,605
  3. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358. IF 5,868
  4. Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, Dimopoulos MA. The Role of Hdac Inhibitors in Patients with Relapsed/Refractory Multiple Myeloma. Leuk Lymphoma. 2014 Jan;55(1):11-8. doi: 10.3109/10428194.2013.797084. IF 2,605
  5. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb;28(2):269-77. IF 9,379
  6. Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B. International Myeloma Working Group recommendations for global myeloma care.  Leukemia. 2014 May;28(5):981-92. doi: 10.1038/leu.2013.293. IF 9,379
  7. Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014;19(8):829-44. doi: 10.1634/theoncologist.2014-0042. IF 4,54
  8. Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weißmann A, Adam Z. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. IF 9,775
  9. Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H, Kuglik P, Vetesnikova E, Pour L, Adam Z, Sevcikova S, Hajek R. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica.  2014 Mar;99(3):511-8. doi: 10.3324/haematol.2013.093500 IF 5,868
  10. Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014 Jun;18(6):947-61. doi: 10.1111/jcmm.12279. IF 3,698
  11. Machálková K., Maisnar V.:Rizikové faktory symptomatického mnohočetného myelomu. Klin. Biochem. Metab., 22 (43), 2014, 2, s. 70-73. ISSN 1210-7921.
  12. Maisnar V.:Efekt dlouhodobého podávání lenalidomidu. Acta medicinae, 2, Special 2014, s. 10-11. ISSN 1805-398X.
  13. Minařík J, Tichý T, Pika T, Bačovský J, Adamová D, Srovnalík K, Krejčí K, Zadražil J, Sčudla V. Bortezomib-based therapy in patients with light chain deposition disease. Vnitr Lek. 2014;60(10):821-6.
  14. Minařík J, Bačovský J, Pika T, Ščudla V Léčba pomalidomidem u relabujícího mnohočetného myelomu – první zkušenosti. Acta medica. [Epub ahead of print]
  15. Minarik J, Hrbek J, Pika T, Novak M, Bacovsky J, Herman M, Hrabalek L, Frysakova L, Pusciznova P, Scudla V. X-Ray in Multiple Myeloma – Not a „Golden Standard“ any More: Case Series. J Bone Mar Res. 2014;2:1-4
  16. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. IF 24,725
  17. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20;32(6):587-600. doi: 10.1200/JCO.2013.48.7934. IF 17,879
  18. Paszekova H, Kryukov F, Kubiczkova L, Hajek R, Sevcikova S. High-Risk Multiple Myeloma: Different Definitions, Different Outcomes? Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):24-30. doi: 10.1016/j.clml.2013.09.004. IF 1,929
  19. Pavlistova L, Zemanova Z, Sarova I, Lhotska H, Berkova A, Spicka I, Michalova K. Change in ploidy status from hyperdiploid to near-tetraploid in multiple myeloma associated with bortezomib/lenalidomide resistance. Cancer Genet. 2014;207(7-8):326-31. pii: S2210-7762(14)00141-0. doi: 10.1016/j.cancergen.2014.06.027. IF 2,417
  20. Pika T, Flodr P, Novák M, Lochman P, Látalová P, Minařík J, Ščudla V. Klinická problematika IgM monoklonálních gamapatií. Klin. Biochem. Metab. 2014;22(43),61-64
  21. Pika T, Kosatíková Z, Juráňová J, Mlčák P. Nekorpuskulární hyperviskózní syndromy v klinické praxi. Interní medicína pro praxi. 2014;16(2):52-54
  22. Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014 Feb;99(2):360-4. doi: 10.3324/haematol.2013.094409 IF 5,868
  23. Raja KR, Plasil M, Rihova L, Pelcova J, Adam Z, Hajek R. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry B Clin Cytom. 2014;86(4):220-8. doi: 10.1002/cyto.b.21109. IF 2,231
  24. Sedlaříková L, Sadílková K, Kubiczková L, Hájek R, Sevčíková S. Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia. Klin Onkol. 2014;27(1):18-23.
  25. Staňková M, Bešše L, Sedlaříková L, Vrábel D, Hájek R, Sevčíková S. Cereblon -  a new target of therapy in the treatment of multiple myeloma. Klin Onkol. 2014;27(5):326-30
  26. Spicka I. Advances in multiple myeloma therapy during two past decades. Comput Struct Biotechnol J. 2014 Jun 11;10(16):38-40. doi: 10.1016/j.csbj.2014.05.005.
  27. Smetana J, Dementyeva E, Kryukov F, Nemec P, Greslikova H, Kupska R, Mikulasova A, Ihnatova I, Hajek R, Kuglik P. Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH. Neoplasma. 2013 Sep 20. doi: 10.4149/neo_2014_008 Neoplasma. 2014;61(1):48-55. IF 1,642
  28. Smetana J, Frohlich J, Zaoralova R, Vallova V, Greslikova H, Kupska R, Nemec P, Mikulasova A, Almasi M, Pour L, Adam Z, Sandecka V, Zahradová L, Hajek R, Kuglik P. Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience. Biomed Res Int. 2014;2014:209670. doi: 10.1155/2014/209670. IF 2,706
  29. Svachova H, Kryukov F, Kryukova E, Sevcikova S, Nemec P, Greslikova H, Rihova L, Kubiczkova L, Hajek R. Nestin expression throughout multistep pathogenesis of multiple myeloma. Br J Haematol. 2014 Mar;164(5):701-9. doi: 10.1111/bjh.12689. IF 4,959
  30. van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014;99(6):984-96. doi: 10.3324/haematol.2013.100552 IF 5,868

 

Jiné výzkumné projekty

  1. Adam Z, Krejčí M, Pour L, Ševčíková E. Therapy of Waldenström´s macroglobulinaemia in the year 2014. Vnitr Lek. 2014 Feb;60(2):139-57.
  2. Adam Z, Řehák Z, Koukalová R, Bortlíček Z, Krejčí M, Pour L, Szturz P, Prášek J, Nebeský T, Adamová Z, Král Z, Mayer J. PET-CT documented complete remission of Erdheim-Chester disease, lasting more than 4 years from treatment initiation with cladribine. Vnitr Lek. 2014 May-Jun;60(5-6):499, 501-11.
  3. Sevčíková S, Kubiczková L, Sedlaříková L, Ríhová L, Kryukov F, Szturz P, Hajek R, Pour L, Adam Z. Impact of anakinra treatment on cytokine and lymphocytes/ monocytes profile of an Erdheim-Chester patient. Klin Onkol. 2014;27(4):276-82.
  4. Szturz P, Sedivá A, Zurek M, Adam Z, Stork J, Cermáková Z, Steyerová P, Vokáčová A, Hrbek J, Sýkora M, Spička I, Mechl Z, Mayer J. Anakinra treatment in Schnitzler syndrome -results of the first retrospective multicenter study in six patients from the Czech Republic. Klin Onkol. 2014;27(2):111-26
  5. Szturz P, Adam Z, Rehák Z, Koukalová R. Xanthelasma palpebrarum responding to interleukin-1 blockade. Intern Med J. 2014 Jun;44(6):617-8. doi:10.1111/imj.12441. IF 1,699
  6. Sčudla V., Pika T., Látalová P., Flodr P., Maisnar V., Hájek R.: Česká myelomová skupina: Diagnostika a stratifikace systémové AL amyloidózy ve světle Doporučení České myelomové skupiny 2013. Klin. Biochem. Metab., 22 (43), 2014, 2, s. 49-60. ISSN 1210-7921.

 

Starší publikace (2012 - 2013)

Starší publikace (2006 - 2011)

Starší publikace (1995 - 2005)